Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
NCT04545710 is a phase 2 interventional trial sponsored by University of California, San Diego. As of 21 Nov 2026, it is active and no longer recruiting. It studies Abemaciclib and Osimertinib in Lung Cancer. The registry lists an enrollment of 18 participants at 1 site in 1 country. The registry lists a start date of 21 Nov 2020 and a primary completion date of 1 Dec 2025.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04545710 |
| Status | Active not recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | University of California, San Diego |
| Enrollment | 18 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Lung Cancer |
| Drugs | Abemaciclib and Osimertinib |
| Start | 21 Nov 2020 |
| Primary completion | 1 Dec 2025 |
| Study completion | 1 Dec 2026 |
| Last update posted | 5 Aug 2024 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Hatim Husain, MD
University of California, San Diego
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ucsd Moores Cancer Center
La Jolla
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04545710
Each answer restates registry values shown on this page.
What is NCT04545710?
NCT04545710 is a phase 2 interventional trial sponsored by University of California, San Diego. It studies Abemaciclib and Osimertinib in Lung Cancer.
Is NCT04545710 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT04545710?
The registry names Hatim Husain, MD (principal investigator, University of California, San Diego) as the overall official.
Where does NCT04545710 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04545710 study?
The registered drug and biological interventions are Abemaciclib and Osimertinib.
When is NCT04545710 expected to complete?
The registry lists a primary completion date of 1 Dec 2025 and a study completion date of 1 Dec 2026. The sponsor last updated the record on 5 Aug 2024.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.